<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01115179</url>
  </required_header>
  <id_info>
    <org_study_id>APSIC 04-014</org_study_id>
    <secondary_id>CER: 04-189</secondary_id>
    <nct_id>NCT01115179</nct_id>
  </id_info>
  <brief_title>Propofol and Perioperative Inflammation</brief_title>
  <official_title>Propofol and/or Its Solvent Modify the Course of Inflammatory Response After Surgical Stress: A Randomized, Controlled, Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The inflammatory properties of propofol are still under debate. Apolipoprotein A-I (Apo A-I)
      is involved in the inflammatory process. This study was designed to determine whether and how
      propofol or its solvent modulate Apo A-I and the inflammatory response after surgical stress.
      The investigators study hypothesis was that propofol might modify the Apo A-I blood levels,
      and thus, modulate the postoperative inflammatory course.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apolipoprotein A-I level</measure>
    <time_frame>24 hours after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6 level</measure>
    <time_frame>5 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP) level</measure>
    <time_frame>24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol level</measure>
    <time_frame>15 min after induction of anesthesia</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anesthesia with isoflurane alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solvent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anesthesia with isoflurane together with the solvent of propofol (intralipid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>Induction with propofol (1.5 to 2mg/kg) and maintenance of anesthesia with propofol 1% (target controlled infusion with concentration levels of 3-5 ug/ml)</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Propofol, Ansiven</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid 10%</intervention_name>
    <description>Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%) as well as the solvent of propofol 1% (Intralipid 10%; corresponding to a target-controlled infusion of propofol with concentration levels of 3-5ug/ml)</description>
    <arm_group_label>Solvent</arm_group_label>
    <other_name>Intralipid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%)</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>NaCl 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists (ASA) I or II

          -  scheduled for uni- or bilateral elective laparoscopic totally extraperitoneal hernia
             repair

        Exclusion Criteria:

          -  Body mass index (BMI) &lt; 18.5 or &gt; 39.9kg/m2

          -  treatments with steroids (&gt;5mg/d prednisone equivalent, for the last 30 days)

          -  with opioids/non-steroidal anti-inflammatory drugs (NSAIDs) for chronic pain during
             the last 30 days

          -  immunosuppression (AIDS, neutropenia &lt;1000 cells/ml, transplant surgery, chemotherapy)

          -  known lipid disorder (triglycerides &gt;2.00mmol/l, low-density lipoprotein
             (LDL)-cholesterol &gt;2.50mmol/l or high-density lipoprotein (HDL)-cholesterol &lt;
             1.00mmol/l)

          -  hypolipemic treatment before admission

          -  thyroid metabolism disorder (thyroid-stimulating hormone &gt;6.0 mUI/l or &lt;0.4mUI/l)

          -  renal insufficiency (creatinine &gt;106umol/l)

          -  liver disorder (bilirubin &gt;20umol/l, thromboplastin time &lt;60%)

          -  insulin dependant diabetes

          -  parenteral nutrition or after any lipid-containing medication (propofol, intralipid,
             etomidate) during the last 30 days

          -  antihypertensive medication with diltiazem or other calcium channel blockers

          -  known chronic alcoholism (men: &gt;65-75 ml alcohol/day)

          -  multidrug abuse (cocaine, heroin, methadone, or other narcotics, sedatives or
             stimulants)

          -  mental illness

          -  known allergy to propofol after randomization:

          -  change of surgical strategy

          -  protocol violation

          -  major bleeding (&gt;0.5l)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bara Ricou, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Service of Intensive Care, Geneva University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oliver Bandschapp, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service of Intensive Care, Geneva University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service of Anesthesiology; Geneva University Hospital</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Chenaud C, Merlani PG, Roux-Lombard P, Burger D, Harbarth S, Luyasu S, Graf JD, Dayer JM, Ricou B. Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation. Crit Care Med. 2004 Mar;32(3):632-7.</citation>
    <PMID>15090939</PMID>
  </reference>
  <reference>
    <citation>Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK 3rd, Roux-Lombard P, Burger D. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood. 2001 Apr 15;97(8):2381-9.</citation>
    <PMID>11290601</PMID>
  </reference>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2010</study_first_submitted>
  <study_first_submitted_qc>May 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2010</study_first_posted>
  <last_update_submitted>May 17, 2010</last_update_submitted>
  <last_update_submitted_qc>May 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Bara Ricou</name_title>
    <organization>Service of Intensive Care, Department APSI, Geneva University Hospital</organization>
  </responsible_party>
  <keyword>propofol</keyword>
  <keyword>inflammation</keyword>
  <keyword>perioperative</keyword>
  <keyword>lipids</keyword>
  <keyword>Apolipoprotein A-I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

